About Aquestive Therapeutics, Inc.
https://www.aquestive.comAquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally.
CEO
Daniel Barber
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 88
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Lake Street
Buy
JMP Securities
Market Outperform
Oppenheimer
Outperform
Piper Sandler
Overweight
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BRATTON CAPITAL MANAGEMENT, L.P.
Shares:9.81M
Value:$34.53M
BLACKROCK, INC.
Shares:6.53M
Value:$22.97M
RTW INVESTMENTS, LP
Shares:6.25M
Value:$22M
Summary
Showing Top 3 of 168
About Aquestive Therapeutics, Inc.
https://www.aquestive.comAquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $12.81M ▲ | $19.78M ▲ | $-15.45M ▼ | -120.61% ▲ | $-0.14 | $-11.03M ▼ |
| Q2-2025 | $10M ▲ | $16.81M ▼ | $-13.55M ▲ | -135.44% ▲ | $-0.14 ▲ | $-9.13M ▲ |
| Q1-2025 | $8.72M ▼ | $24.43M ▲ | $-22.93M ▼ | -262.96% ▼ | $-0.24 ▼ | $-15.76M ▼ |
| Q4-2024 | $11.87M ▼ | $20.93M ▲ | $-17.05M ▼ | -143.72% ▼ | $-0.19 ▼ | $-12.7M ▼ |
| Q3-2024 | $13.54M | $17.39M | $-11.51M | -84.99% | $-0.13 | $-7.15M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $129.06M ▲ | $163.56M ▲ | $167.67M ▲ | $-4.11M ▲ |
| Q2-2025 | $60.54M ▼ | $93.7M ▼ | $166.29M ▲ | $-72.59M ▼ |
| Q1-2025 | $68.66M ▼ | $102.23M ▲ | $163.16M ▲ | $-60.93M ▼ |
| Q4-2024 | $71.55M ▼ | $101.42M ▼ | $161.58M ▲ | $-60.16M ▼ |
| Q3-2024 | $77.89M | $109.96M | $155.38M | $-45.42M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-15.45M ▼ | $-12.65M ▼ | $-235K ▼ | $81.41M ▲ | $68.53M ▲ | $-12.88M ▼ |
| Q2-2025 | $-13.55M ▲ | $-7.91M ▲ | $-107K ▲ | $-100K ▼ | $-8.12M ▼ | $-8.02M ▲ |
| Q1-2025 | $-22.93M ▼ | $-23.4M ▼ | $-135K ▼ | $20.65M ▲ | $-2.89M ▲ | $-23.54M ▼ |
| Q4-2024 | $-17.05M ▼ | $-6.49M ▲ | $-15K ▲ | $157K ▲ | $-6.35M ▲ | $-6.5M ▲ |
| Q3-2024 | $-11.51M | $-11.88M | $-80K | $-17K | $-11.98M | $-11.96M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 CoDevelopment and Research Fees | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 License and Royalty Revenue | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 Manufacture and Supply Revenue | $20.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 Manufactured Product Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|---|
 NonUS | $10.00M ▲ | $10.00M ▲ | $0 ▼ | $0 ▲ |
 UNITED STATES | $20.00M ▲ | $0 ▼ | $10.00M ▲ | $10.00M ▲ |
CEO
Daniel Barber
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 88
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Lake Street
Buy
JMP Securities
Market Outperform
Oppenheimer
Outperform
Piper Sandler
Overweight
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BRATTON CAPITAL MANAGEMENT, L.P.
Shares:9.81M
Value:$34.53M
BLACKROCK, INC.
Shares:6.53M
Value:$22.97M
RTW INVESTMENTS, LP
Shares:6.25M
Value:$22M
Summary
Showing Top 3 of 168